Navigation Links
Collaborative Software Initiative Addresses State Governments' Requirements for Meeting Infectious Disease Compliance
Date:5/19/2008

CSI and State of Utah team to deliver first open source infectious disease

management system to meet CDC mandate

PORTLAND, Ore., May 19 /PRNewswire/ -- Collaborative Software Initiative (CSI), the company that brings like-minded organizations together to work on collaborative software at a fraction of the cost, today announced the release of the first open source, web-based infectious disease reporting and management system.

The system will both protect citizens and meet the requirements for the Center for Disease Control and Prevention's (CDC's) National Electronic Disease Surveillance System (NEDSS). NEDSS is the infrastructure cornerstone for the nation's Public Health Information Network (PHIN).

The disease reporting and management system, which is being piloted in Utah, will be adaptable in all 50 states and available under an open source license later this year. It is designed to support local health departments in the early detection and investigation of individual cases and local clusters of communicable disease, while simultaneously meeting the state and federal needs of outbreak control, disease surveillance and epidemiologic research.

According to the December 2007 report from Trust for America's Health, only eight states are currently fully prepared to protect the public from disease, disasters and bio-terrorism. Existing NEDSS solutions are either too expensive or outdated and don't meet the states' needs. CSI's open source infectious disease reporting and management system, developed with the collaborative software development model, is significantly less expensive and meets all local, state, and federal requirements.

The collaborative software development model, based on a unique combination of industry standards, open source business practices, and lean software development techniques was chosen in order to bring multiple stakeholders with a common need together.

"We are excited by th
'/>"/>

SOURCE Collaborative Software Initiative
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
2. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
3. Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally
4. Biomoda Announces Collaborative Agreement With New Mexico Tech
5. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety
6. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
7. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
8. Basil Zimmo Joins Finesse Solutions as Vice-President of Software
9. United BioSource Acquires Leading Publication Planning Software and Services Company
10. Amnis Announces Release of Powerful New Image Data Analysis Software
11. Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4